<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453088</url>
  </required_header>
  <id_info>
    <org_study_id>PRO# 1307</org_study_id>
    <nct_id>NCT01453088</nct_id>
  </id_info>
  <brief_title>Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older</brief_title>
  <official_title>(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hackensack University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hackensack University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators are comparing this standard regimen to the newly established
      regimen of melphalan and bortezomib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the investigators are comparing this standard regimen to the newly established
      regimen of melphalan and bortezomib.

      Conditioning Regimens:

      Treatment arm A Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion
      via a central or peripheral vein over 30 minutes to one hour.

      Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.

      Dosing will be based on body surface area calculated using actual body weight

      Stem cell infusion:

      Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of
      melphalan. The infusion of peripheral blood stem cells will be done in accordance with the
      Blood and Marrow Transplant program standard operating procedures.

      Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day
      starting on day+3 then daily starting on day 9 until engraftment (at least).

      Treatment arm B

      Bortezomib:

      Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral
      vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at
      least 20 hrs after the start of the melphalan infusion on day -1.

      Dosing will be based on actual body weight. Dexamethasone is administered at a dose of 20 mg
      IV prior to each bortezomib infusion.

      Melphalan:

      Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central
      or peripheral vein over 30 minutes to one hour.

      Melphalan will be given as a single dose (not split over 2 or more days) and given of day-2.

      Dosing will be based body surface area calculated using actual body weight

      Stem cell infusion:

      Stem cell infusion will occur on day 0 and will be at least 18 hours after the infusion of
      the bortezomib. The infusion of peripheral blood stem cells will be done in accordance with
      the Blood and Marrow Transplant program standard operating procedures.

      Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day
      starting on day+3 then daily starting on day 9 until engraftment (at least).

      Post-transplant Supportive Care will be administered in accordance to the Blood and Marrow
      Transplant program standard operating procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2010</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib.</measure>
    <time_frame>Participants will be followed post transplant for a minimum of 2 years, and after that may be monitored as part of the study indefinitely</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the response rate, overall survival and toxicity of high-dose melphalan versus high-dose melphalan and bortezomib</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.
Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.
Dosing will be based on body surface area calculated using actual body weight
Stem cell infusion:
Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.
Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib:
Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.
Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.
Dosing will be based on body surface area calculated using actual body weight
Stem cell infusion:
Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.
Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Phenylalanine mustard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib:
Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1.</description>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of multiple myeloma less than 12 months since initiation of
             systemic therapy

          -  Age ≥60 years at time of transplantation

          -  KPS 70-100%

          -  Recovery from complications of prior therapy

        Exclusion Criteria:

          -  Diagnosis other than multiple myeloma

          -  Chemotherapy or radiotherapy within 8 days of initiating treatment in this study

          -  Prior dose-intense therapy within 56 days of initiating treatment in this study

          -  Uncontrolled bacterial, viral, fungal or parasitic infections

          -  Uncontrolled CNS metastases

          -  Known amyloid deposition in heart

          -  Organ dysfunction

          -  LVEF &lt;40% or cardiac failure not responsive to therapy

          -  FVC, FEV1 or DLCO &lt; 40% of predicted and/or receiving supplementary continuous oxygen

          -  Evidence of hepatic synthetic dysfunction or total bilirubin &gt; 2x or AST &gt; 3x ULN

          -  Measured creatinine &lt; 20ml/min

          -  Sensory peripheral neuropathy grade 4 within 14 days of enrollment

          -  Karnofsky score &lt; 70%

          -  Life expectancy limited by other co-morbid illnesses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Donato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Theurer Cancer Center at Hackensack University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Donato, MD</last_name>
    <phone>201-996-5900</phone>
    <email>Michele.Donato@HackensackMeridian.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariefel Vendivil</last_name>
    <phone>551-996-5828</phone>
    <email>Mariefel.Vendivil@HackensackMeridian.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Gunn, RN, BSN</last_name>
      <phone>202-687-4773</phone>
      <email>keg91@georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julia Varga, RN, MSN</last_name>
      <phone>202-687-7354</phone>
      <email>jmv78@georgetown.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pashna Munshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariefel Vendivil</last_name>
      <phone>551-996-5828</phone>
      <email>Mariefel.Vendivil@HackensackMeridian.org</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Ortega</last_name>
      <phone>551-996-3923</phone>
      <email>Andrea.Orgeta@HackensackMeridian.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michele Donato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Vesole, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott D Rowley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Baker, APN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michele Boonstra, APN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noa Biran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David S Siegel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joshua Richter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phyllis McKiernan, APN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Skarbnik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary DiLorenzo, APN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22.</citation>
    <PMID>10363983</PMID>
  </reference>
  <reference>
    <citation>Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol. 2005 Sep 1;23(25):5943-9.</citation>
    <PMID>16135465</PMID>
  </reference>
  <reference>
    <citation>Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994 Feb 17;330(7):484-9. Review.</citation>
    <PMID>8289856</PMID>
  </reference>
  <reference>
    <citation>Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Fournie B, Mazieres B, Pris J, Laurent G. Intensive combined therapy for previously untreated aggressive myeloma. Blood. 1992 Mar 1;79(5):1130-6.</citation>
    <PMID>1536941</PMID>
  </reference>
  <reference>
    <citation>Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996 Jul 11;335(2):91-7.</citation>
    <PMID>8649495</PMID>
  </reference>
  <reference>
    <citation>Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R; InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003 Dec 25;349(26):2495-502. Erratum in: N Engl J Med. 2004 Jun17;350(25):2628.</citation>
    <PMID>14695409</PMID>
  </reference>
  <reference>
    <citation>Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001 Sep;114(4):822-9.</citation>
    <PMID>11564069</PMID>
  </reference>
  <reference>
    <citation>Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997 Feb 1;89(3):789-93.</citation>
    <PMID>9028309</PMID>
  </reference>
  <reference>
    <citation>Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added].</citation>
    <PMID>16432076</PMID>
  </reference>
  <reference>
    <citation>Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2006 Feb 20;24(6):937-44. Epub 2006 Jan 17.</citation>
    <PMID>16418495</PMID>
  </reference>
  <reference>
    <citation>Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115-23.</citation>
    <PMID>9753033</PMID>
  </reference>
  <reference>
    <citation>Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J; Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005 Dec 1;106(12):3755-9. Epub 2005 Aug 16.</citation>
    <PMID>16105975</PMID>
  </reference>
  <reference>
    <citation>Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003 May 8;348(19):1875-83.</citation>
    <PMID>12736280</PMID>
  </reference>
  <reference>
    <citation>Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001 May 1;61(9):3535-40.</citation>
    <PMID>11325813</PMID>
  </reference>
  <reference>
    <citation>Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000 Jun 15;95(12):4008-10.</citation>
    <PMID>10845942</PMID>
  </reference>
  <reference>
    <citation>Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B; Scientific Advisors of the International Myeloma Foundation. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4(6):379-98. Review. Erratum in: Hematol J. 2004;5(3):285.</citation>
    <PMID>14671610</PMID>
  </reference>
  <reference>
    <citation>Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol. 2003 Nov;123(3):484-9.</citation>
    <PMID>14617011</PMID>
  </reference>
  <reference>
    <citation>Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet JC. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998 Nov 1;92(9):3131-6.</citation>
    <PMID>9787148</PMID>
  </reference>
  <reference>
    <citation>Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P; Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005 Dec 20;23(36):9227-33. Epub 2005 Nov 7.</citation>
    <PMID>16275936</PMID>
  </reference>
  <reference>
    <citation>Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004 Feb 15;64(4):1546-58.</citation>
    <PMID>14989251</PMID>
  </reference>
  <reference>
    <citation>Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000 Jun;18(12):2354-62. Erratum in: J Clin Oncol. 2004 Jan 1;22(1):209.</citation>
    <PMID>10856094</PMID>
  </reference>
  <reference>
    <citation>Fossella F. Docetaxel + Cisplatin (DC) and Docetaxel + Carboplatin (DCb) vs Vinorelbine + Cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer (NSCLC): Results of a multicenter, randomized phase III study. European Journal of Cancer, European Cancer Conference, ECCO 11, 2001; Lisbon, Portugal. 37(suppl 6):S154. Abstract 562</citation>
  </reference>
  <reference>
    <citation>Gahrton G, Svensson H, Björkstrand B, Apperley J, Carlson K, Cavo M, Ferrant A, Fouillard L, Gratecos N, Gratwohl A, Guilhot F, Lambertenghi Deliliers G, Ljungman P, Masszi T, Milligan DW, Powles RL, Reiffers J, Samson JD, Stoppa AM, Vernant JP, Volin L, Wallvik J. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1999 Oct;24(7):741-5.</citation>
    <PMID>10516677</PMID>
  </reference>
  <reference>
    <citation>Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol. 1998 Dec;16(12):3796-802.</citation>
    <PMID>9850024</PMID>
  </reference>
  <reference>
    <citation>Gouyette A, Hartmann O, Pico JL. Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol. 1986;16(2):184-9.</citation>
    <PMID>3948304</PMID>
  </reference>
  <reference>
    <citation>Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev. 1992 Sep;6(3):163-73. Review.</citation>
    <PMID>1422285</PMID>
  </reference>
  <reference>
    <citation>Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, Bourhis JH, Caillot D, Boasson M, Abgrall JF, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood. 1995 Jun 1;85(11):3077-85.</citation>
    <PMID>7756641</PMID>
  </reference>
  <reference>
    <citation>Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001 Apr 1;61(7):3071-6.</citation>
    <PMID>11306489</PMID>
  </reference>
  <reference>
    <citation>Hollmig K, Stover J, Talamo G, et al. Addition of bortezomib (Velcade™) to high dose melphalan (VelMel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM). Blood 2004;104:266a</citation>
  </reference>
  <reference>
    <citation>Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004 Oct;127(2):165-72.</citation>
    <PMID>15461622</PMID>
  </reference>
  <reference>
    <citation>Kergueris MF, Milpied N, Moreau P, Harousseau JL, Larousse C. Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res. 1994 Nov-Dec;14(6A):2379-82.</citation>
    <PMID>7825976</PMID>
  </reference>
  <reference>
    <citation>LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002 Sep 1;62(17):4996-5000.</citation>
    <PMID>12208752</PMID>
  </reference>
  <reference>
    <citation>Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant. 2002 Dec;30(12):873-8.</citation>
    <PMID>12476279</PMID>
  </reference>
  <reference>
    <citation>Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem. 2000 May;46(5):673-83.</citation>
    <PMID>10794750</PMID>
  </reference>
  <reference>
    <citation>McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983 Oct 8;2(8354):822-4.</citation>
    <PMID>6137651</PMID>
  </reference>
  <reference>
    <citation>Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, Desikan K, Munshi N, Fassas A, Mattox S, Vesole D, Crowley J, Barlogie B. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant. 1998 May;21(9):887-92.</citation>
    <PMID>9613780</PMID>
  </reference>
  <reference>
    <citation>Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15;101(6):2377-80. Epub 2002 Nov 7.</citation>
    <PMID>12424198</PMID>
  </reference>
  <reference>
    <citation>NATHANS D, FAHEY JL, POTTER M. The formation of myeloma protein by a mouse plasma cell tumor. J Exp Med. 1958 Jul 1;108(1):121-30.</citation>
    <PMID>13549645</PMID>
  </reference>
  <reference>
    <citation>Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002 Nov 15;20(22):4420-7.</citation>
    <PMID>12431963</PMID>
  </reference>
  <reference>
    <citation>Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005 Apr 15;105(8):3058-65. Epub 2004 Dec 30.</citation>
    <PMID>15626743</PMID>
  </reference>
  <reference>
    <citation>Paccagnella A, Chiarion-Sileni V, Soesan M, Baggio G, Bolzonella S, De Besi P, Casara D, Frizzarin M, Salvagno L, Favaretto A, et al. Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. Cancer. 1991 Sep 1;68(5):975-80.</citation>
    <PMID>1913491</PMID>
  </reference>
  <reference>
    <citation>Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Dammacco F, Ciccone G, Boccadoro M. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004 Nov 15;104(10):3052-7. Epub 2004 Jul 20.</citation>
    <PMID>15265788</PMID>
  </reference>
  <reference>
    <citation>Pandit S, Vesole DH. Relapsed multiple myeloma. Curr Treat Options Oncol. 2001 Jun;2(3):261-9. Review.</citation>
    <PMID>12057126</PMID>
  </reference>
  <reference>
    <citation>Papandreou C, Daliani D, Millikan RE, Tu S, Pagliaro L, Adam J. Phase I Study of Intravenous (I.V.) Proteasome Inhibitor PS-341 in Patients (Pts) with Advanced Malignancies. Proc Am Soc Clin Oncol, 2001. Abstract 340</citation>
  </reference>
  <reference>
    <citation>Pineda-Roman M, Fox MH, Hollmig KA, et al. Retrospective analysis of fractionated high-dose melphalan (F-Mel) and bortezomib-thalidomide-dexamethasone (VTD) with autotransplant (AT) support for advanced and refractory multiple myeloma (AR-MM). Blood 2006;108:884a</citation>
  </reference>
  <reference>
    <citation>Pinguet F, Martel P, Fabbro M, Petit I, Canal P, Culine S, Astre C, Bressolle F. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res. 1997 Jan-Feb;17(1B):605-11.</citation>
    <PMID>9066587</PMID>
  </reference>
  <reference>
    <citation>Pink MM, Pien CS, Ona VO, Worland P, Adams J, Kauffman MG. PS-341 enhances chemotherapeutic effect in human xenograft models. Proc Am Assoc Cancer Res, 2002; San Francisco, CA. Abstract 787</citation>
  </reference>
  <reference>
    <citation>Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007 Mar;39(5):279-83. Epub 2007 Jan 29.</citation>
    <PMID>17262062</PMID>
  </reference>
  <reference>
    <citation>Reece PA, Hill HS, Green RM, Morris RG, Dale BM, Kotasek D, Sage RE. Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol. 1988;22(4):348-52.</citation>
    <PMID>3168148</PMID>
  </reference>
  <reference>
    <citation>Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17.</citation>
    <PMID>12826635</PMID>
  </reference>
  <reference>
    <citation>Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16;352(24):2487-98.</citation>
    <PMID>15958804</PMID>
  </reference>
  <reference>
    <citation>Richardson et al, Bortezomib Continues to Demonstrate Superior Efficacy Compared With High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trial. Blood, 2005; 106: Abstract 2547.</citation>
  </reference>
  <reference>
    <citation>Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 1;27(34):5713-9. doi: 10.1200/JCO.2009.22.2679. Epub 2009 Sep 28.</citation>
    <PMID>19786667</PMID>
  </reference>
  <reference>
    <citation>Rowley SD, Siegel, D, Donato ML,et al. Combination melphalan and bortezomib conditioning with autologous hematopoeitic stem cell support in patients with advanced multiple myeloma. A phase I/II study. Blood 2009;114:499</citation>
  </reference>
  <reference>
    <citation>Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995 Jul;13(7):1786-99. Review.</citation>
    <PMID>7602368</PMID>
  </reference>
  <reference>
    <citation>Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, Anaissie E, Naucke S, Ayers D, Spoon D, Vesole D, Tricot G, Barlogie B. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999 Jan 1;93(1):51-4.</citation>
    <PMID>9864145</PMID>
  </reference>
  <reference>
    <citation>Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood. 2002 Jul 1;100(1):224-9.</citation>
    <PMID>12070031</PMID>
  </reference>
  <reference>
    <citation>Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999 Sep;5(9):2638-45.</citation>
    <PMID>10499643</PMID>
  </reference>
  <reference>
    <citation>Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant. 1995 Jul;16(1):7-11.</citation>
    <PMID>7581132</PMID>
  </reference>
  <reference>
    <citation>Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, Vesole DH, Jagannath S, Meyers R, Barlogie B. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996 Jun;2(6):947-52.</citation>
    <PMID>9816255</PMID>
  </reference>
  <reference>
    <citation>Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A, Barlogie B. Predicting long-term (&gt; or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002 Jan;116(1):211-7.</citation>
    <PMID>11841419</PMID>
  </reference>
  <reference>
    <citation>Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, Crowley J. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood. 1994 Aug 1;84(3):950-6.</citation>
    <PMID>7913845</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

